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ABSTRACT 
Objectives: Symptom-based criteria to diagnose irritable bowel syndrome (IBS) positively 
perform only modestly. Our aim was to assess whether including other items from the clinical 
history and limited diagnostic evaluation improves their performance. 
Methods: We collected complete symptom, colonoscopy, and histology data from 318 
consecutive, unselected adult patients with lower gastrointestinal (GI) symptoms in 
secondary care. All participants underwent colonoscopy, with relevant organic findings 
recorded. The reference standard used to define the presence of true IBS was patient-reported 
lower abdominal pain or discomfort associated with a change in bowel habit, in the absence 
of organic GI disease. Sensitivity, specificity, and positive and negative likelihood ratios 
(LRs), with 95% confidence intervals, were calculated for Rome III criteria, as well as for 
modifications, incorporating nocturnal stools, results of simple blood tests (hemoglobin and 
C-reactive protein (CRP)), measures of somatization, and/or affective disorders (hospital 
anxiety or depression scale (HADS) score). 
Results: The sensitivity and specificity of the Rome III criteria for identifying IBS was 
69.6%, and 82.0% respectively, with positive and negative LRs of 3.87 and 0.37. Clinically 
useful enhancements in positive LRs were provided by combining Rome III criteria with: (a) 
high level of somatization (7.27); (b) normal hemoglobin and CRP with HADS score of ≥8 
(5.04); (c) normal hemoglobin and CRP with a high level of somatization (7.56), or; (d) no 
nocturnal passage of stool with a high level of somatization (17.3). Specificity was ≥95% 
with each of these modifications. 
Conclusions: Incorporating nocturnal stools, somatization, and affective disorders from the 
clinical history, and hemoglobin and CRP measurements, enhances the positive LR and 
specificity of symptom-based Rome III criteria for IBS.   
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What is current knowledge? 
 Current symptom-based diagnostic criteria, such as the Rome III criteria, for irritable 
bowel syndrome (IBS) perform only modestly.  
 Biomarkers for IBS perform no better than symptom-based diagnostic criteria, and are 
probably more expensive.  
 A recent systematic review and meta-analysis suggested that approaches to 
diagnosing IBS that used combinations of symptoms with biomarkers and/or 
measures of anxiety or depression were more accurate.  
 
What is new here? 
 The sensitivity and specificity of the Rome III criteria for identifying IBS was 69.6%, 
and 82.0% respectively, with positive and negative LRs of 3.87 and 0.37. 
 The addition of various combinations of markers of either somatization or 
anxiety/depression, and normal blood results, led to clinically useful enhancements to 
the performance of the Rome III criteria.  
 These findings could be used to inform future iterative processes to develop 
diagnostic criteria for the functional gastrointestinal disorders.  
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INTRODUCTION 
 Irritable bowel syndrome (IBS) is a chronic functional gastrointestinal (GI) disorder, 
characterized by lower abdominal pain or discomfort in association with a change in stool 
form and/or frequency. 1 The condition has a prevalence of up to 20% in Western 
populations, 2 and is associated with significant morbidity. IBS results in reduced quality of 
life for the individual, and represents a considerable economic burden to society due, in part, 
to the costs to healthcare systems of managing the condition. 3  There is an expectation that 
physicians should try to reduce these costs by making a positive diagnosis of IBS, using 
symptom-based diagnostic criteria, whilst simultaneously minimizing invasive investigations. 
4,5  
 Physicians may be reluctant to adopt this approach in clinical practice, as GI diseases 
manifest as a limited repertoire of symptoms, and those of IBS can mimic organic diseases 
such as inflammatory bowel disease, 6 microscopic colitis, 7 bile acid diarrhea, 8,9 or celiac 
disease. 10 The current “gold standard” for symptom-based diagnosis of IBS are the Rome III 
criteria, 1 but these have only been validated in one large study from Canada, 11 and 
performed modestly in distinguishing IBS from organic GI disease. However, one of the 
issues in diagnostic test studies for IBS is the lack of an accepted reference standard. Most 
investigators have used a normal colonoscopy as confirmation of a diagnosis of IBS;12 that is, 
physicians still regard IBS as a diagnosis of exclusion, which is perhaps justified by the 
modest performance of the different symptom-based criteria for IBS proposed over the last 
four decades.11,13 Indeed, the current level of diagnostic confidence, based exclusively on 
these criteria, has not reduced the performance of testing such as colonoscopy and biopsies in 
some settings,14 despite the desirability to enhance high-value care. 
 Recently, research has focused on the development of novel fecal, serum, and 
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imaging-based biomarkers that may more accurately predict a diagnosis of IBS, or subgroups 
of IBS. 15–19 Some of the proposed biomarkers (which are unfortunately not widely available) 
may also serve as therapeutic targets and enhance outcomes. Despite this, a systematic review 
and meta-analysis that evaluated all generally available approaches to diagnose IBS 
demonstrated that biomarkers alone performed similarly to symptom-based criteria, 20 while 
adding to the cost of care. Interestingly, studies using combinations of symptoms with 
biomarkers and/or measures of psychological wellbeing reported improved diagnostic 
accuracy. 17,21 Other investigators have reported that the absence of ”red flag” features, such 
as nocturnal symptoms, 22,23 or incorporating the results of simple laboratory tests, including 
hemoglobin and erythrocyte sedimentation rate, 24 may increase the ability to distinguish 
between functional and organic lower GI diseases.  
Our aim, based on these observations, was to conduct a diagnostic accuracy study to 
examine whether the performance of the current gold-standard in symptom-based criteria for 
IBS could be improved if combined with other relevant markers. We hypothesized that the 
inclusion of the results of simple laboratory tests, absence of nocturnal symptoms, 
identification of markers of either somatization or anxiety/depression, or combinations 
thereof, would increase the performance of the Rome III criteria in diagnosing IBS. Proof of 
enhancement in the diagnostic performance of symptom-based criteria could result in a 
reliable, inexpensive, and easily administrable clinical evaluation, and represent a 
considerable advance in enabling clinicians to make a positive diagnosis of IBS confidently 
in the clinic.  
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METHODS 
 
Participants and Setting 
 We recruited unselected, consecutive patients aged ≥16 years newly referred from 
primary care to secondary care for consideration of investigation of GI symptoms. All 
patients were approached in six of the medical gastroenterology outpatient clinics of Leeds 
Teaching Hospitals Trust, West Yorkshire, United Kingdom. The hospitals provide 
secondary care services to a local population of almost 800,000 people in the North of 
England. The only exclusion criteria were an inability to understand written English, as the 
questionnaires utilized were self-administered. Potentially eligible subjects were given a 
study information sheet at their initial clinic visit, before consultation with a 
gastroenterologist. Those agreeing to participate provided written informed consent at that 
visit. The local ethics committee approved the study (reference 13/YH/0216), with 
recruitment commencing in January 2014, and continuing through to December 2015. During 
the 2-year recruitment period the six involved clinics saw approximately 2200 new outpatient 
referrals. As the study was conducted in routine clinical practice, the diagnostic evaluation of 
the recruited patients was not standardized, and was left at the discretion of the responsible 
physician. We did not mandate a minimum panel of blood tests, or collection of colonic 
biopsy specimens in all patients. However, all patients agreeing to participate were asked to 
complete the questionnaires detailed below. In addition, fecal calprotectin testing was not 
used routinely within our department during the time this study was conducted.  
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Data Collection and Synthesis 
 
Demographic and Symptom data 
 All demographic and symptom data were collected prospectively at the initial clinic 
visit. Questionnaire data were entered into a database by trained researchers who were not 
involved in the clinical care of the patient, thus ensuring assessors were blinded to symptom 
status. Demographic data of interest included age, height (in meters), and weight (in 
kilograms), from which body mass index (BMI) was calculated, gender, tobacco and alcohol 
use, marital status, educational level, and ethnicity. The Rome III diagnostic questionnaire for 
adult functional GI disorders was used to collect data on GI symptoms.25  We also asked 
patients whether they experienced nocturnal passage of stool, which was recorded as 
occurring never, rarely, sometimes, often, most of the time, or always, with a symptom 
frequency of sometimes or greater used to define its presence  
 
Mood and Somatization Data 
We used the validated hospital anxiety and depression scale (HADS) to collect 
information about mood.26 This 14-item instrument contains seven questions concerning 
anxiety, and another seven depression. Each of these questions is scored from 0 to 3, giving a 
total possible score of 21 for anxiety or depression separately. A score of ≥8 was used to 
define possible anxiety or depression.  
We used the validated patient health questionnaire-15 (PHQ-15) to assess for 
evidence of somatization-type behavior.27 The individual symptom items are provided in 
Supplementary Table 1. Each of these questions is scored on a scale from 0 to 2, giving a 
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total possible score of 30. A score of ≥15 is the validated threshold used to define high levels 
of somatization.  
 
Baseline Tests in Diagnostic Evaluation 
We also collected information from patients’ case notes and computerized records. 
We recorded hemoglobin level (normal for males ≥13.5g/dL, normal for females ≥11.5g/dL) 
and C-reactive protein (CRP) (normal <5mg/L) at the initial clinic visit. We also recorded the 
initial diagnosis made by the physician who consulted with the patient, as well as the final 
diagnosis made after investigation to the level deemed appropriate by each individual 
consulting physician.   
 
Definition of IBS 
The presence or absence of Rome III-defined IBS among individual patients was 
assigned according to the scoring algorithm proposed for use with the Rome III questionnaire 
(Supplementary Table 2).  
 
Colonoscopic and Histopathological Data  
All included patients underwent complete colonoscopy to the cecum or terminal 
ileum. The endoscopy units in Leeds Teaching Hospitals Trust employ colonoscopes from 
both Olympus and Fujinon. Bowel preparation was either a combination of polyethylene 
glycol and sodium picosulfate, or polyethylene glycol alone, depending on renal function. All 
endoscopists performing colonoscopic examinations remained blinded to the questionnaire 
data of the patient. Findings were recorded using the ADAM reporting system (Fujifilm, 
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Europe), with reports accessed by study investigators in order to record the final colonoscopic 
diagnosis for each included patient. Findings classified as consistent with organic disease at 
colonoscopy are provided in Table 1. 
Biopsy specimens were obtained at the discretion of the endoscopist performing the 
colonoscopy. Standard policy during these colonoscopies in any patient with chronic diarrhea 
and a macroscopically normal colon is to take two biopsies from the right colon, two from the 
left colon, and two from the rectum. All biopsies were interpreted by experienced GI 
histopathologists, who remained blinded to the questionnaire data of the patient. 
Histopathological findings were accessed using computerized records to record the final 
histopathological diagnosis. Findings classified as being consistent with organic disease after 
histopathological examination of biopsy specimens are also provided in Table 1.  
Using these data, patients were classified according to the presence or absence of 
organic lower GI disease. Individuals had to have no evidence of an organic explanation for 
their symptoms at both colonoscopy and histopathological examination of biopsy specimens 
in order to be classified as exhibiting no organic lower GI disease. 
 
Reference Standard to Define the Presence of True IBS 
 The reference standard used to define the presence of true IBS was lower abdominal 
pain or discomfort occurring at least three days per month over the last 3 months, in 
association with a change in bowel habit, and in the absence of organic lower GI disease after 
colonoscopy and histopathological examination of colonic biopsies, if obtained, which would 
explain these symptoms. Exclusion of celiac disease with distal duodenal biopsy was also 
undertaken, if celiac serology was positive.  
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Statistical Analysis 
In order to assess whether those who underwent colonoscopy and provided complete 
symptom data were representative of all patients recruited, demographic data were compared 
between those undergoing colonoscopy who completed the symptom questionnaire, and those 
who completed the symptom questionnaire but did not undergo colonoscopy, using a χ2 test 
for categorical data, and an independent samples t-test for continuous data, with a mean and 
standard deviation (SD). Due to multiple comparisons a 2-tailed P value of <0.01 was 
considered statistically significant for these analyses. We compared organic findings in those 
meeting the Rome III criteria for IBS, with those who did not, using Fisher’s exact test, as 
numbers in each cell were relatively small. These statistical analyses were performed using 
SPSS for Windows version 21.0 (SPSS Inc, Chicago, IL, USA). 
The first aim of the study was to ascertain the performance of the Rome III criteria for 
IBS in determining the presence of true IBS versus the reference standard of symptoms 
suggestive of IBS and a negative colonoscopy described above. To that end, sensitivity, 
specificity, and positive and negative predictive values, and their 95% confidence intervals 
(CIs), were calculated for the Rome III criteria versus the reference standard using 
StatsDirect version 2.8.0 (StatsDirect Ltd, Sale, Cheshire, England). The positive likelihood 
ratio (LR) and negative LR, and their 95% CIs, were also calculated. The positive LR can be 
calculated from the formula: positive LR = sensitivity / (1-specificity). The negative LR is 
derived from the formula: negative LR = (1-sensitivity) / specificity. We performed these 
analyses for all individuals recruited who underwent colonoscopy for investigation of their 
lower GI symptoms, and provided complete Rome III symptom data. However, in clinical 
practice the challenge is often distinguishing between IBS-D and other potential organic GI 
causes of diarrhea. With this in mind, we performed post hoc analyses including only those 
participants reporting either ≥4 stools per day, or loose, mushy, or watery stools.  
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The advantage of using LRs over predictive values is that LRs do not vary to the same 
degree as predictive values with a change in disease prevalence. As a rule of thumb, a 
positive LR of more than 10 is useful for ruling in a disease, and a negative LR of less than 
0.1 is useful for ruling out a disease. However, in diseases of higher prevalence, the positive 
LR threshold required to cause a useful increase in probability that will result in a change of 
management may be lower. In a recently published systematic review, the authors assumed 
“medical certainty” for a novel biomarker in diagnosing IBS as a post-test probability 
(derived from the pre-test probability and positive LR) of >80%.28 At this threshold, in a 
secondary or tertiary care population with a prevalence of IBS of around 50%, a test with a 
positive LR of ≥5 would identify IBS with a post-test probability of 86.5%.  
The second aim was to compare the performance of proposed modifications to the 
Rome III criteria, by including information on nocturnal passage of stools, the physician’s 
working diagnosis at the initial consultation, laboratory results of hemoglobin and CRP, and 
measures of anxiety/depression and somatization, against the reference standard described 
above. Again, sensitivities, specificities, positive and negative predictive values, and positive 
and negative LRs were calculated for each of these modifications individually, and as 
combinations.  
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RESULTS 
 There were 1002 consecutive patients (mean age 54.4 years (range 16 to 92 years), 
638 (63.7%) female) who gave informed consent and were recruited into the study between 
January 2014 and December 2015. Of these, 318 (31.7%) patients (mean age 54.0 years 
(range 18 to 92 years), 216 (67.9%) female) underwent colonoscopy for investigation of their 
lower GI symptoms, and provided complete Rome III symptom data (Figure 1, flow chart). 
Comparison of the demographic data of this group with those who did not undergo 
colonoscopy is provided in Table 2. Patients providing complete symptom data and 
undergoing colonoscopy had a higher BMI and were more likely to meet the Rome III criteria 
for IBS, but there were no other significant differences between the two groups. Patients with 
IBS with diarrhea (IBS-D) were more likely to undergo colonoscopy, but not patients with 
IBS with constipation or those with mixed stool pattern IBS.  
Among the 318 individuals providing complete symptom and colonoscopy data, 98 
(30.8%) met the Rome III criteria for IBS. The mean age of these 98 patients was 46.7 years, 
and 73 (74.5%) were female. There were 286 (89.9%) patients who had a hemoglobin check, 
178 (56.0%) with a CRP measurement, 212 (66.7%) with celiac serology, and 215 (67.6%) 
who had colonic biopsy specimens obtained. Relevant organic findings after colonoscopy and 
histopathological interpretation of biopsy specimens, plus duodenal biopsy in those with 
positive celiac serology, in those that met the Rome III criteria compared with the 220 
patients that did not are detailed in Table 3. There were no significant differences in the 
prevalence of any of these between the two groups. 
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Performance of the Rome III Criteria for IBS Against the Reference Standard 
Of 79 (24.8%) individuals meeting the reference standard of symptoms suggestive of 
IBS and a negative colonoscopy, 55 met the Rome III criteria, giving a sensitivity of 69.6% 
(Table 4). Among the 239 patients without IBS according to this reference standard, 196 did 
not meet the Rome III criteria, giving a specificity of 82.0%. Positive and negative LRs of the 
Rome III criteria were 3.87 (95% CI 2.85 to 5.26) and 0.37 (95% CI 0.26 to 0.51) 
respectively.  
 
Effect of Additional Factors from the History and Simple Laboratory Tests on the 
Diagnostic Performance of Rome III Criteria 
  The effect of incorporating nocturnal passage of stools, a physician’s working 
diagnosis at the initial consultation that this was IBS, the presence of anemia or a raised CRP, 
HADS score of ≥8, or high levels of somatization into the Rome III criteria are also shown in 
Table 4. Sensitivities in diagnosing IBS ranged from 18.2% for presence of the Rome III 
criteria, no nocturnal passage of stool, and a high level of somatization to 50.0% for presence 
of the Rome III criteria and a physician’s initial impression that the diagnosis was IBS. 
Specificities ranged from 79.7% for presence of the Rome III criteria and a physician’s initial 
impression that the diagnosis was IBS, to 99.0% for presence of the Rome III criteria, no 
nocturnal passage of stool, and a high level of somatization.  
Improved positive LRs were obtained by combining the Rome III criteria with a high 
level of somatization alone (positive LR 7.27; 95% CI 3.74 to 14.2); a normal hemoglobin 
and CRP with a HADS score of ≥8 (positive LR 5.04; 95% CI 2.48 to 10.2); a normal 
hemoglobin and CRP with a high level of somatization (positive LR 7.56; 95% CI 2.63 to 
21.7); and no nocturnal passage of stool with a high level of somatization (positive LR 17.3; 
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95% CI 4.45 to 67.6). Note that for all these combinations, positive LRs were above the 
threshold of ≥5 that has been recommended to define a potentially useful test, providing the 
prevalence of IBS in the population under study is 50% or more.28 Specificity approached 
95% or more with all these modifications; thus the risk of a missed diagnosis of organic GI 
disease would be small, as the false positive rate was extremely low.  
When the analyses were restricted to participants who reported either ≥4 stools per 
day, or loose, mushy, or watery stools, there were similar enhancements of positive LRs (in 
some instances, almost two-fold those for the Rome III criteria alone) with the incorporation 
of additional factors from the clinical history and simple laboratory tests into the Rome III 
criteria (Table 5). 
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DISCUSSION 
 This study validated the symptom-based Rome III criteria for IBS against an accepted 
clinical reference standard. These criteria performed modestly, with a positive and negative 
LR of 3.87 and 0.37 respectively. In addition, we examined the effect of addition of nocturnal 
symptoms, factors related to somatization, affective disorders, and hemoglobin and CRP 
measurements on the accuracy of the symptom-based Rome III criteria. A combination of the 
Rome III criteria with a high level of somatization, a normal hemoglobin and CRP with a 
HADS score of ≥8, a normal hemoglobin and CRP with a high level of somatization, or no 
nocturnal passage of stool with a high level of somatization all provided positive LRs of ≥5. 
In a secondary or tertiary referral population in a University Hospital practice with a 
prevalence of IBS of 50% or more, a positive LR of this magnitude would be clinically useful 
for the diagnosis of IBS, identifying IBS with a post-test probability of >85%.28   
 The performance of the Rome III criteria in this study is remarkably similar to that 
observed in a previous validation study, which also used a reference standard of the 
combination of symptoms suggestive of IBS and a negative colonoscopy. 11 In that prior 
study from Canada,11  which included >1800 patients, the positive and negative LRs of the 
Rome III criteria were 3.35 (95% CI 2.97-3.79) and 0.39 (95% CI 0.39-0.46) respectively. 
Unlike the current study, the previous study did not incorporate other features of the clinical 
history or simple laboratory tests with the Rome III criteria. Sensitivity analyses were 
conducted in the Canadian study,11 where individuals reporting lower GI alarm symptoms, 
including rectal bleeding, anemia, weight loss, or a family history of colorectal cancer were 
excluded. However, the addition of lower GI alarm symptoms resulted in only a small 
improvement in the positive LR. Few other studies have attempted to modify the symptom-
based Rome criteria.22 Vanner et al. examined the effect of excluding patients with “red flag” 
features, including nocturnal GI symptoms, on the Rome I criteria.22 However, this was a 
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small retrospective study, and the investigators did not attempt to separate nocturnal GI 
symptoms from other alarm symptoms, which are reported frequently by patients without 
organic disease.29  
 Psychological or affective disorders have been shown to be strongly associated with 
IBS. 30 There was an improvement in diagnostic test accuracy when other investigators added 
these to a biomarker panel in a recent study.17 Rates of somatoform-type behavior, in 
particular, have been shown to be significantly higher in patients with IBS,31 and to 
differentiate IBS from health with greater accuracy, compared with markers of anxiety and 
depression. 32 The results of our study support this finding, with a greater accuracy when a 
combination of the Rome III criteria and high level of somatization was used, as compared 
with a combination of the Rome III criteria and HADS scores. Incorporating the presence of 
co-existent functional GI disorders into our modifications to the Rome III criteria may also 
have improved their performance. However, unlike in IBS, some other functional GI 
disorders are diagnoses of exclusion. For instance, a diagnosis of functional heartburn would 
not be made on symptoms alone, but only after a negative upper endoscopy and normal pH 
and impedance studies. As our study did not mandate the relevant investigations to confirm 
that, when the appropriate symptoms were reported, the cause was indeed another functional 
GI disorder we were therefore unable to examine this issue. 
 We propose that the performance of the modifications to the Rome III criteria used in 
the current study can be best appreciated by comparing them with the accuracy of 
biomarkers. In general, biomarkers have been shown to perform no better than symptom-
based diagnostic criteria in IBS,20 and in some cases are probably not clinically useful outside 
of a research or tertiary care setting, due to their complex or invasive nature e.g. brain 
imaging, or endoscopy and biopsy with specialized histopathology.33–36 Furthermore, many 
of the studies that have validated biomarkers have been limited by the fact that their utility in 
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IBS was compared with healthy controls, when it would be more useful to assess the 
performance of the biomarker in distinguishing between IBS and organic disease. 
Alternatively, other appraisals of biomarkers have used IBS-enriched populations, reducing 
their generalizability to a clinical setting. 20   
One biomarker that is available for use in clinical practice currently was examined for 
its ability to differentiate IBS-D from inflammatory bowel disease, celiac disease, or health.19 
In this study, antibodies to cytolethal toxin B, a toxin commonly produced by Campylobacter 
jejuni, and to vinculin, a cell adhesion protein, performed best when differentiating IBS-D 
from inflammatory bowel disease, with positive LRs of 5.2 and 2.0 respectively. However, 
the authors used an enriched sample of cases, that consisted of a cohort of patients enrolled in 
a large randomized clinical trial of rifaximin, with >80% of participants having IBS-D. Thus, 
the LRs may not be reproducible in other populations, or in those with IBS not associated 
with diarrhea. This underlines the importance of our findings in a consecutive, unselected 
secondary care population, where various combinations of the Rome III criteria, two routine 
blood tests, and a symptom-item checklist, appeared accurate and would be inexpensive to 
administer as a diagnostic test.  
The improved performance of the Rome III criteria when combined with relevant 
blood tests and markers of somatization and anxiety/depression is perhaps not surprising 
given the findings of other investigators, summarized in a recent meta-analysis.20  Studies 
that have used symptoms with clinical laboratory tests, biomarkers, and markers of 
psychological disorders, have shown improved differentiation of IBS from organic GI 
diseases. This direction was first suggested by Kruis and colleagues in a statistical model in 
1984,24 and outperformed symptom-based diagnostic criteria alone in a previous meta-
analysis.12  Tibble et al. also demonstrated a high diagnostic accuracy of the Rome I criteria 
in combination with both a fecal calprotectin and a small intestinal permeability ratio.21  
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However, the Kruis model may be limited by its complexity, and the approach of Tibble et al. 
is not clinically applicable, given the lack of availability of measures of small intestinal 
permeability. We suspect that the proposed models did not progress beyond a research setting 
because of their complexity. Other markers for measurement of small intestinal and colonic 
permeability have been proposed since the earlier study by Tibble et al., based on the ratio of 
saccharide excretion,37 although there is still no generally available, clinically applicable, and 
universally accepted test of intestinal permeability at present.   
There are methodological strengths of our study. First, it was conducted in a large, 
unselected population referred to secondary care, so the results are likely to be generalizable 
to patients with suspected IBS seen in usual clinical care by gastroenterologists. The sample 
size, although smaller than the previous validation study of the Rome III criteria,11 is larger 
than most other studies that have assessed the accuracy of diagnostic tests for IBS.20  Second, 
it was designed to adhere to the STARD guidelines for the reporting of studies of diagnostic 
accuracy, with consecutive patients recruited, assessors blinded, and accepted references 
standard used. Third, it used inexpensive factors to modify the symptom-based criteria, and 
these lend themselves to application in primary or secondary care. 
 There are some limitations to the study. Not all patients that underwent colonoscopy 
provided complete symptom data, and we were therefore unable to include these individuals 
in our analyses. However, this number was comparatively small, with almost 90% of patients 
providing full data. Most of the patients included in the study were White Caucasian, 
meaning that these results may not be applicable to other ethnicities. The mean age of 
included individuals was relatively high at 54 years, which probably reflects our use of a 
negative colonoscopy as a reference standard, meaning that there is some selection bias and 
that the results may therefore not be generalizable to a younger population. In addition, the 
reference standard we used in our analyses included symptom data from the questionnaire, 
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which may have resulted in an overestimation of the accuracy of the Rome III criteria and its 
modifications, and a negative colonoscopy. There are other conditions that may mimic IBS, 
such as bile acid diarrhea, small intestinal bacterial overgrowth, or fructose and lactose 
intolerance,38–40 which are not excluded by a negative colonoscopy. These were not screened 
for routinely in this study, which was conducted within usual clinical practice. However, the 
prevalence of unequivocal small intestinal bacterial overgrowth in patients presenting with 
symptoms suggestive of IBS is probably less than 5%.41 For similar reasons, we did not 
mandate a minimum diagnostic work up in terms of a panel of standardized blood tests or 
colonic biopsy specimens in all patients. The modifications to symptom-based criteria in our 
current study enhanced the diagnosis of IBS, but do not necessarily identify actionable 
features of the disorder. Thus, the recently validated additional measurements of colonic 
transit or of bile acid metabolism still provide the best biomarkers to individualize therapy in 
subsets of IBS patients.18,42 Finally, the approaches suggested by our findings may not 
completely change physician behavior, due to uncertainty or fear of a missed organic 
diagnosis, which is reflected by the fact that significantly more patients who met the Rome III 
criteria for IBS were referred for colonoscopy in this study. However, further proof of the 
validity of this approach in prospective cohorts will enhance the confidence with which 
physicians can make a positive diagnosis of IBS, which was the intent of the original 
symptom-based criteria proposed by Manning et al.13  
 In summary, the performance of the Rome III criteria in diagnosing IBS was similar 
to that observed in a previous validation study from a cohort in Canada.11 Important novel 
findings from this study were that modifying these criteria, with questionnaires concerning 
nocturnal symptoms, anxiety/depression, and somatization, in addition to simple laboratory 
tests, improved their diagnostic performance. An inexpensive clinical test that combines 
symptoms with clinical markers, which is easily administered in a routine care setting, and 
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accurate enough to allow the physician to confidently make a positive diagnosis of IBS would 
be highly desirable, and may have important implications for enhanced value care.  
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Table 1. Findings Consistent with Organic Disease at Colonoscopy, or After 
Histopathological Interpretation of Colonic Biopsies. 
At Colonoscopy After Histopathological Interpretation of Colonic 
Biopsies 
Evidence of colitis  
Evidence of terminal ileitis (inflammation or 
ulceration) 
Colorectal carcinoma 
Colonic stricture 
Evidence of radiation-induced colorectal disease 
Colonic adenocarcinoma  
Rectal adenocarcinoma 
Ulcerative colitis 
Crohn’s disease 
Inflammatory bowel disease-unclassifiable 
Microscopic colitis 
Ischemic colitis 
Radiation enteropathy  
Ulceration seen macroscopically at colonoscopy with 
non-specific inflammation on histological examination 
Neuroendocrine tumor 
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Table 2. Demographics and Baseline Characteristics of Patients Who Underwent 
Colonoscopy and Provided Complete Symptom Data Compared with Those That Did 
Not Undergo Colonoscopy. 
 Underwent colonoscopy 
and provided complete 
Rome III symptom data 
(n = 318) 
Did not undergo 
colonoscopy 
(n = 642) 
P value* 
Mean age in years (SD) 54.0 (16.3) 54.6 (18.1) 0.57 
Mean BMI (SD) 27.2 (6.0) 26.2 (5.3) 0.02 
Female gender (%) 216 (67.9) 402 (62.6) 0.11 
Tobacco use (%) 74 (23.3) 149 (23.2) 0.99 
Alcohol use (%) 171 (53.8) 351 (54.7) 0.87 
Marital status (%) 
Married or cohabiting 
Divorced or separated 
Never Married 
Widowed 
 
177 (55.7) 
44 (13.8) 
59 (18.6) 
26 (8.2) 
 
354 (55.1) 
74 (11.5) 
116 (18.1) 
73 (11.4) 
 
 
 
 
0.38 
Educational level (%) 
Elementary 
High school 
College or technical school 
University 
Postgraduate 
 
2 (0.6) 
144 (45.3) 
77 (24.2) 
47 (14.8) 
29 (9.1) 
 
3 (0.5) 
277 (43.1) 
137 (21.3) 
91 (14.2) 
55 (8.6) 
 
 
 
 
 
0.98 
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White Caucasian ethnicity (%) 292 (91.8) 573 (89.3) 0.25 
Met Rome III criteria for IBS (%) 
IBS-D 
IBS-C 
IBS-M 
98 (30.8) 
46 (14.6) 
5 (1.6) 
45 (14.2) 
126 (19.6) 
32 (5.0) 
25 (3.9) 
60 (9.3) 
<0.001 
<0.001 
0.08 
0.03 
HADS score ≥8 (n = 829) 144/292 (49.3) 278/537 (51.8) 0.50 
High level of somatization (n = 725) 57/258 (22.1) 99/467 (21.2) 0.78 
*P value for independent samples t-test for continuous data and Pearson χ2 for comparison of 
categorical data. 
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Table 3. Prevalence of Organic Disease in Patients Meeting the Rome III Criteria 
Compared With Those Who Did Not. 
 Met Rome III criteria 
for IBS 
(n = 98) 
Did not meet Rome III 
criteria for IBS 
(n = 220) 
P value* 
Ulcerative colitis (%) 2 (2.0) 2 (0.9) 0.59 
Crohn’s disease (%) 4 (4.1) 2 (0.9) 0.08 
Inflammatory bowel 
disease-unclassifiable 
(%) 
0 (0) 2 (0.9) 0.52 
Nonspecific GI 
ulceration (%) 
1 (1.0) 4 (1.8) 1.0 
Collagenous colitis (%) 4 (4.1) 12 (5.5) 0.78 
Lymphocytic colitis (%) 2 (2.0) 9 (4.1) 0.51 
Colorectal cancer (%) 0 (0) 2 (0.9) 1.0 
Celiac disease (%) 2 (2.0) 5 (2.3) 1.0 
*P value for Fisher’s exact test for comparison of categorical data. 
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Table 4. Diagnostic Accuracy of the Rome III Criteria, and Modifications to the Rome III Criteria with the Inclusion of No Nocturnal 
Passage of Stool, Physician’s Initial Impression that this was IBS, Biomarkers or Markers of Affective Disorders, or a Combination 
Thereof, versus the Reference Standard. 
 Number of 
patients 
providing data in 
the analysis 
Sensitivity  
(95% CI) 
Specificity  
(95% CI ) 
Positive 
predictive value  
(95% CI)  
Negative 
predictive value  
(95% CI) 
Positive 
likelihood ratio 
(95% CI) 
Negative 
likelihood ratio 
(95% CI) 
Rome III criteria 
alone 
318 69.6%  
(58.3% – 79.5%) 
82.0%  
(76.5% – 86.7%) 
56.1%  
(46.3% – 65.5%) 
89.1%  
(84.3% – 92.6%) 
3.87  
(2.85 – 5.26) 
0.37 
(0.26 – 0.51) 
Rome III criteria 
and no nocturnal 
passage of stool 
311 33.3%  
(23.1% – 44.9%) 
91.0%  
(86.6% – 94.3%) 
55.3%  
(41.3% – 68.6%) 
80.3%  
(75.1% – 84.7%) 
3.70  
(2.21 – 6.14) 
0.73 
(0.61 – 0.84) 
Rome III criteria 
and physician’s 
initial impression 
that this was IBS 
112 50.0%  
(33.4% – 66.6%) 
79.7%  
(68.8% – 88.2%) 
55.9%  
(39.5% – 71.1%) 
75.6%  
(65.1% – 83.8%) 
2.47  
(1.42 – 4.27) 
0.63 
(0.43 – 0.84) 
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Rome III criteria 
and normal 
hemoglobin and 
CRP 
208 49.0%  
(34.8% – 63.4%) 
89.2%  
(83.2% – 93.6%) 
59.5%  
(44.5% – 73.0%) 
84.3%  
(78.0% – 89.1%) 
4.53 
(2.67 – 7.64) 
0.57  
(0.42 – 0.73) 
Rome III criteria 
and HADS score 
≥8 
292 47.2%  
(35.3% – 59.4%) 
89.1%  
(84.2% – 92.9%) 
58.6%  
(45.8% – 70.4%) 
83.8%  
(78.5% – 87.9%) 
4.33  
(2.76 – 6.76) 
0.59  
(0.46 – 0.72) 
Rome III criteria 
and high level of 
somatization 
258 37.9%  
(26.2% – 50.7%) 
94.8%  
(90.6% – 97.5%) 
71.4%  
(55.0% – 83.7%) 
81.6%  
(76.0% – 86.1%) 
7.27  
(3.74 – 14.2) 
0.66 
(0.53 – 0.77) 
Rome III criteria, 
normal 
hemoglobin and 
CRP, and HADS 
score ≥8 
195 34.0%  
(20.9% – 49.3%) 
93.2%  
(87.9% – 96.7%) 
61.5%  
(42.5% – 77.6%) 
81.7%  
(75.1% – 86.8%) 
5.04  
(2.48 – 10.2) 
0.71  
(0.55 – 0.84) 
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Rome III criteria, 
normal 
hemoglobin and 
CRP, and high 
level of 
somatization 
165 24.4% 
(12.4% – 40.3%) 
96.8% 
(92.0% – 99.1%) 
71.4% 
(45.4% – 88.3%) 
79.5% 
(72.3% – 85.1%) 
7.56 
(2.63 – 21.7) 
0.78 
(0.63 – 0.90) 
Rome III criteria, 
no nocturnal 
passage of stool, 
and HADS score 
≥8 
290 22.2% 
(13.3% – 33.6%) 
95.4% 
(91.7% – 97.8%) 
61.5% 
(42.5% – 77.6%) 
78.8% 
(73.5% – 83.3%) 
4.84 
(2.33 – 10.0) 
0.82 
(0.70 – 0.91) 
Rome III criteria, 
no nocturnal 
passage of stool, 
and high level of 
somatization 
256 18.2%  
(9.8% – 29.6%)  
99.0% 
(96.3% – 99.9%) 
85.7% 
(60.1% – 96.0%) 
77.7% 
(72.0% – 82.5%) 
17.3 
(4.45 – 67.6) 
0.83 
(0.72 – 0.90) 
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Table 5. Diagnostic Accuracy of the Rome III Criteria, and Modifications to the Rome III Criteria with the Inclusion of No Nocturnal 
Passage of Stool, Physician’s Initial Impression that this was IBS, Biomarkers or Markers of Affective Disorders, or a Combination 
Thereof, versus the Reference Standard Among Patients Presenting with Diarrhea. 
 Number of 
patients 
providing data in 
the analysis 
Sensitivity  
(95% CI) 
Specificity  
(95% CI ) 
Positive 
predictive value  
(95% CI)  
Negative 
predictive value  
(95% CI) 
Positive 
likelihood ratio 
(95% CI) 
Negative 
likelihood ratio 
(95% CI) 
Rome III criteria 
alone 
252 68.0%  
(56.2% – 78.3%) 
76.8%  
(69.9% – 82.4%) 
55.4%  
(44.7% – 65.8%) 
85.0%  
(78.5% – 90.2%) 
2.94 
(2.16 – 4.01) 
0.42 
(0.29 – 0.57) 
Rome III criteria 
and no nocturnal 
passage of stool 
251 30.7%  
(20.5% – 42.4%) 
89.2%  
(83.7% – 93.4%) 
54.8%  
(38.7% – 70.2%) 
75.1%  
(68.7% – 80.8%) 
2.84  
(1.65 – 4.85) 
0.77 
(0.65 – 0.89) 
Rome III criteria 
and physician’s 
initial impression 
that this was IBS 
100 54.3%  
(36.7% – 71.2%) 
76.9%  
(64.8% – 86.5%) 
55.9%  
(37.9% – 72.8%) 
75.8%  
(63.6% – 85.5%) 
2.35  
(1.38 – 4.03) 
0.59 
(0.39 – 0.84) 
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Rome III criteria 
and normal 
hemoglobin and 
CRP 
163 51.0%  
(36.3% – 65.6%) 
85.1%  
(77.2% – 91.1%) 
59.5%  
(43.3% – 74.4%) 
80.2%  
(71.9% – 86.9%) 
3.42 
(2.05 – 5.72) 
0.58  
(0.41 – 0.75) 
Rome III criteria 
and HADS score 
≥8 
237 46.4%  
(34.3% – 58.8%) 
85.7%  
(79.5% – 90.6%) 
57.1%  
(43.2% – 70.3%) 
79.6%  
(72.9% – 85.2%) 
3.25  
(2.07 – 5.07) 
0.63  
(0.49 – 0.77) 
Rome III criteria 
and high level of 
somatization 
207 38.1%  
(26.2% – 51.2%) 
93.1%  
(87.6% – 96.6%) 
70.6%  
(52.5% – 84.9%) 
77.5%  
(70.5% – 83.5%) 
5.49  
(2.83 – 10.7) 
0.67 
(0.53 – 0.79) 
Rome III criteria, 
normal 
hemoglobin and 
CRP, and HADS 
score ≥8 
158 34.8%  
(21.4% – 50.3%) 
91.1%  
(84.2% – 95.6%) 
61.5%  
(40.6% – 79.8%) 
77.3%  
(69.2% – 84.1%) 
3.90  
(1.93 – 7.83) 
0.72  
(0.55 – 0.86) 
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Rome III criteria, 
normal 
hemoglobin and 
CRP, and high 
level of 
somatization 
131 25.0% 
(12.7% – 41.2%) 
95.6% 
(89.1% – 98.8%) 
71.4% 
(41.9% – 91.6%) 
74.4% 
(65.5% – 82.0%) 
5.69 
(2.00 – 16.3) 
0.78 
(0.62 – 0.91) 
Rome III criteria, 
no nocturnal 
passage of stool, 
and HADS score 
≥8 
237 20.3% 
(11.6% – 31.7%) 
94.1% 
(89.3% – 97.1%) 
58.3% 
(36.6% – 77.9%) 
74.2% 
(67.8% – 79.9%) 
3.41 
(1.61 – 7.16) 
0.85 
(0.73 – 0.94) 
Rome III criteria, 
no nocturnal 
passage of stool, 
and high level of 
somatization 
207 17.5%  
(9.1% – 29.1%)  
98.6% 
(95.1% – 99.8%) 
84.6% 
(54.6% – 98.1%) 
73.2% 
(66.4% – 79.3%) 
12.6 
(3.23 – 49.5) 
0.84 
(0.72 – 0.92) 
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FIGURE LEGENDS 
Figure 1. Flow of Study Participants. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1002 consecutive 
patients with GI 
symptoms 
enrolled 
360 patients 
underwent 
complete 
colonoscopy 
642 patients did 
not undergo 
colonoscopy 
318 patients 
provided complete 
Rome III symptom 
and colonoscopy 
data 
42 patients did not 
provide complete 
symptom or 
colonoscopy data 
